WallStreetZenWallStreetZen

NASDAQ: NTLA
Intellia Therapeutics Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Intellia Therapeutics revenue was $45.57M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q1 2025) ending on Mar 31, 2025 was $16.6M, up 29.2% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, NTLA annual revenue was $57.9M, with 59.6% growth year-over-year.

NTLA past revenue growth

How has NTLA's revenue growth performed historically?

Company
-13.37%
Industry
150.01%
Market
20.37%
NTLA's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
NTLA's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
NTLA's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

NTLA revenue history

Current Revenue
$45.6M
Current Earnings
-$525.9M
Current Profit Margin
-1,154.1%

Be the first to know when NTLA announces revenue.

NTLA Revenue History By Year

NTLA Yearly RevenueNTLA RevenueNTLA ChangeNTLA Revenue Growth
2024-12-31$57.88M$21.60M+59.55%
2023-12-31$36.28M-$15.85M-30.40%
2022-12-31$52.12M$19.07M+57.69%
2021-12-31$33.05M-$24.94M-43.01%
2020-12-31$57.99M$14.89M+34.55%
2019-12-31$43.10M$12.67M+41.63%
2018-12-31$30.43M$4.32M+16.53%
2017-12-31$26.12M$9.64M+58.49%
2016-12-31$16.48M$10.44M+172.65%
2015-12-31$6.04MN/AN/A

1 of 1

Intellia Therapeutics Revenue FAQ

What was NTLA's revenue last quarter?

On Invalid Date, Intellia Therapeutics (NASDAQ: NTLA) reported Q1 2025 revenue of $16.63 million up 42.54% year over year. In the same quarter last year, Intellia Therapeutics's revenue was $28.94 million.

What was Intellia Therapeutics's revenue in 2024?

Intellia Therapeutics's annual revenue for the twelve months ending Dec 31, 2024 was $57.88 million, a 59.55% increase year over year.

How much does Intellia Therapeutics make in a day?

Based on Intellia Therapeutics annual revenue for the past five years, NTLA makes an average of $130,038.36 per day.

What was Intellia Therapeutics's annual revenue growth in the past year?

As of Q4 2025, Intellia Therapeutics's revenue has grown -13.37% year over year. This is 163.38 percentage points lower than the US Biotechnology industry revenue growth rate of 150.01%. Intellia Therapeutics's revenue in the past year totaled $45.57 million.

How much does Intellia Therapeutics make in a year?

Intellia Therapeutics's revenue by year for the past five years is:
  • Intellia Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $57.88 million, a 59.55% increase year over year.
  • Intellia Therapeutics's annual revenue for Dec 31, 2023 was $36.28 million, a 30.4% decrease from 2022.
  • Intellia Therapeutics's annual revenue for 2022 was $52.12 million, a 57.69% increase from 2021.
  • Intellia Therapeutics's annual revenue for 2021 was $33.05 million, a 43.01% decrease from 2020.
  • Intellia Therapeutics's annual revenue for 2020 was $57.99 million, a 34.55% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.